Methods of treating endometriosis and other noncancer gynecological disorders with hemp extract

Patent metadata

Field	Value
Publication number	US-11986505-B2
Application number	US-202318299810-A
Country	US
Kind code	B2
Filing date	Apr 13, 2023
Priority date	Oct 26, 2021
Publication date	May 21, 2024
Grant date	May 21, 2024

Abstract

A method for treating a noncancerous gynecological disorder comprising: administering to a patient and effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.

First claim

What is claimed is:

1. A composition for treatment of a noncancerous gynecological disorder (NCGD) selected from the group consisting of: endometriosis, an ovarian endometrioma, a deep endometriosis, dysmenorrhea, and fibroids; wherein the composition comprises between 1% and 99% by weight of a cannabis extract (CE) and wherein the CE of the composition comprises:
a. an extract selected from the group consisting of: a full spectrum hemp extract (FSHE), a broad spectrum hemp extract (BSHE), a cannabidiol (CBD) isolate, and combinations thereof;
b. a carrier at between 1% and 99% by weight of the composition;
c. one or more excipients at between 1% and 50% by weight of the composition; and
d. the CE formulated for administration oromucosally and intravaginally as two separate doses.

2. The composition of claim 1 wherein the composition is acidic with a pH between 3.5 and 6.

3. The composition of claim 1 wherein the CE comprises between 10 mg and 4,250 mg of cannabidiol (CBD).

4. The composition of claim 1 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% by weight of the composition.

5. The composition of claim 1 wherein the composition comprises an oil or a fat as a carrier.

6. The composition of claim 1 wherein the composition further comprises at least one additional cannabinoid at between 0.1% and 10% weight percentage of the composition wherein the at least one additional cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.

7. A composition for intravaginal application for treatment of a noncancerous gynecological disorder (NCGD) selected from the group consisting of:
endometriosis, an ovarian endometrioma, a deep endometriosis, dysmenorrhea, and fibroids; wherein the composition comprises between 1% and 99% by weight of a cannabis extract (CE) and wherein the CE of the composition comprises:
a. an extract selected from the group consisting of: a full spectrum hemp extract (FSHE), a broad spectrum hemp extract (BSHE), a cannabidiol (CBD) isolate, and combinations thereof;
b. between 0.1% and 10% of a cannabidiolic acid (CBDA) isolate;
c. a carrier at between 1% and 99% by weight of the composition; and
d. one or more excipients at between 1% and 50% by weight of the composition.

8. The composition of claim 7 wherein the composition is acidic with a pH between 3.5 and 6.

9. The composition of claim 7 wherein the CE comprises between 10 mg and 4,250 mg of cannabidiol (CBD).

10. The composition of claim 7 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% by weight of the composition.

11. The composition of claim 7 wherein the composition comprises an oil or a fat as a carrier.

12. The composition of claim 7 wherein the composition further comprises at least one additional cannabinoid at between 0.1% and 10% weight percentage of the composition wherein the at least one additional cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.

Assignees

• Ecofibre Usa Inc
• Univ Newcastle

Inventors

• Capano Alexandra M
• Tanwar Pradeep Singh
• Nance Alex

Classifications

• A61K36/185 Primary

  Magnoliopsida (dicotyledons) · CPC title

• A61K36/3482 Primary

  Cannabis · CPC title

• A61K31/658

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A61K31/105

  Persulfides (thiuram disulfides A61K31/145; thiosulfonic acids A61K31/185) · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title